Systemic Scleroderma is a type of chronic autoimmune condition that is characterized by several symptoms such as skin hardening, skin thickening, and inflammation in various organs. Skin thickening is the most frequent symptom of such disease. One of the key factors driving the demand and development of the systemic scleroderma treatment industry is the rapid increase in the number of government initiatives and programs aimed at raising awareness about the available treatment options. Furthermore, continuing technical advances would contribute to the global market’s growth in the years to come. Scleroderma’s increasing prevalence and screening rates, as well as a rise in disposable income, are all contributing to the market’s expansion.
Major Trends and Developments in Systemic Scleroderma Treatment Market
- The immunosuppressant segment led the systemic scleroderma treatment market, accounting for a majority of shares. Since there is no cure for this condition, a wide variety of drug types are prescribed to alleviate symptoms. An immunosuppressant is the most common since this category includes many biologics from well-known companies including Roche.
- Market growth is expected to be fueled by the arrival of new drugs in the market for systemic scleroderma treatment, as well as in increasing awareness programs by the market players. For instance, Pfizer Inc. announced the completion of phase-3 clinical trials for Revatio, a drug used to treat pulmonary hypertension in newborns, in June 2020.
- Boehringer Ingelheim obtained European Commission approval for nintedanib in November 2020, which is used in adults with systemic sclerosis-associated interstitial lung disease. ALPN-101, an Abbvie pipeline treatment for systemic lupus erythematosus has recently completed a Phase-3 trial.
Geographically, North America Holds the Highest Market Share
North America led the systemic scleroderma treatment market, accounting majority of the total share. Biologics are gradually being used in developed countries, resulting in substantial growth of regional growth. The major growth driver is increased access to newly discovered immunosuppressants along with beneficial reimbursement policies. Furthermore, Europe follows North America in terms of market share, owing to higher usage of biosimilars and generics for off-label treatment of systemic scleroderma. The growth of the systemic scleroderma treatment market in the Asia Pacific is expected to expand significantly, owing to the introduction of small molecules and biologics to treat patients.
The demand for systemic scleroderma treatment accounted for high growth and a lot of unmet patient needs in the last few years. Mergers and acquisitions, as well as alliances, are being used by pharmaceutical giants to gain a greater global market share. Janssen Pharmaceutical, a division of Johnson & Johnson Services, Inc., completed the acquisition of Actelion Pharmaceuticals Ltd., strengthening its foothold in the systemic scleroderma treatment market. Increased penetration of this type of medication and their enhanced effectiveness over existing substitutes such as methotrexate, cyclophosphamide, and mycophenolate mofetil, these treatments will prevail before the arrival of curative in clinical trials.
Deep-dive Insights on Systemic Scleroderma Treatment Market by Polaris Market Research: https://www.polarismarketresearch.com/industry-analysis/systemic-scleroderma-treatment-market/request-for-sample